Brainstorm Cell Therapeutics Files 8-K on Shareholder Nominations

TL;DR

Brainstorm Cell Therapeutics filed an 8-K about shareholder board nominations.

AI Summary

On July 29, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report detailing shareholder nominations for its board of directors. This filing is related to the company's ongoing corporate governance and strategic direction.

Why It Matters

This filing indicates active shareholder engagement and potential changes in board composition, which could influence the company's future strategy and leadership.

Risk Assessment

Risk Level: medium — Shareholder nominations can signal potential shifts in company strategy or governance, introducing uncertainty.

Key Players & Entities

• Brainstorm Cell Therapeutics Inc. (company) — Registrant
• July 29, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 1325 Avenue of Americas (address) — Business address

FAQ

Key Financial Figures

• $0.00005 — nge on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market L

Filing Documents

• tm2420468d1_8k.htm (8-K) — 28KB
• 0001104659-24-083959.txt ( ) — 199KB
• bcli-20240729.xsd (EX-101.SCH) — 3KB
• bcli-20240729_lab.xml (EX-101.LAB) — 33KB
• bcli-20240729_pre.xml (EX-101.PRE) — 22KB
• tm2420468d1_8k_htm.xml (XML) — 4KB

08 Shareholder Director Nominations

Item 5.08 Shareholder Director Nominations. On July 29, 2024, the Board of Directors (the "Board") of Brainstorm Cell Therapeutics Inc. (the "Company") approved that the Company's 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting") will be held virtually on Monday, September 16, 2024, at 10:00 a.m. Eastern time. The record date for the determination of stockholders of the Company entitled to receive notice of and to vote at the 2024 Annual Meeting shall be the close of business on August 12, 2024. Because the date of the 2024 Annual Meeting differs by more than thirty (30) days from the anniversary date of the Company's 2023 Annual Meeting of Stockholders, which was held on December 18, 2023, pursuant to Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the Company is hereby providing notice of the updated deadlines for stockholder proposals for inclusion in the Company's proxy materials pursuant to Rule 14a-8 under the Exchange Act, notices of stockholder proposal outside the processes of Rule 14a-8 under the Exchange Act, and notices of director nomination pursuant to Rule 14a-19 under the Exchange Act, which shall supersede the original deadlines therefor as provided in the Company's proxy statement for the Company's 2023 Annual Meeting of Stockholders filed with the SEC on November 8, 2023. Proposals of stockholders intended for inclusion in the Company's proxy statement for the 2024 Annual Meeting in accordance with Rule 14a-8 must be received by the Company at its principal executive offices no later than August 12, 2024, which the Board has determined to be a reasonable time before the Company expects to begin in print and send its proxy materials in accordance with Rule 14a-8(e). Any such proposal must also comply with the requirements as to form and substance established by the SEC in order to be included in the proxy statement relating to the 2024 Annual Meeting. Pursuant to Rule 14a-4 under the Excha

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRAINSTORM CELL THERAPEUTICS INC. Date: July 30, 2024 By: /s/ Chaim Lebovits Chaim Lebovits Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR